Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $136.5 million.

  • Beam Therapeutics' Operating Expenses rose 1302.94% to $136.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $522.0 million, marking a year-over-year decrease of 194.06%. This contributed to the annual value of $479.1 million for FY2024, which is 1355.27% down from last year.
  • As of Q3 2025, Beam Therapeutics' Operating Expenses stood at $136.5 million, which was up 1302.94% from $128.6 million recorded in Q2 2025.
  • Beam Therapeutics' Operating Expenses' 5-year high stood at $200.4 million during Q1 2021, with a 5-year trough of $59.0 million in Q2 2021.
  • For the 5-year period, Beam Therapeutics' Operating Expenses averaged around $119.4 million, with its median value being $120.8 million (2024).
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 60653.01% in 2021, then plummeted by 5775.16% in 2022.
  • Beam Therapeutics' Operating Expenses (Quarter) stood at $114.6 million in 2021, then dropped by 4.83% to $109.0 million in 2022, then soared by 68.16% to $183.3 million in 2023, then fell by 29.03% to $130.1 million in 2024, then increased by 4.92% to $136.5 million in 2025.
  • Its last three reported values are $136.5 million in Q3 2025, $128.6 million for Q2 2025, and $126.8 million during Q1 2025.